Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Terminated 2Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Thoracic 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 250Lung Neoplasms 174Small Cell Lung Carcinoma 37Breast Neoplasms 37Neoplasms 25Neoplasm Metastasis 19Adenocarcinoma of Lung 17Ovarian Neoplasms 14Mesothelioma, Malignant 14Melanoma 13Stomach Neoplasms 12Mesothelioma 12Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Prostatic Neoplasms 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Renal Cell 9Lung Diseases 7Colonic Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Head and Neck Neoplasms 6Triple Negative Breast Neoplasms 5Thymoma 5Sarcoma 5Pleural Effusion, Malignant 5Carcinoma, Ovarian Epithelial 5Carcinoma 5

Interventions

Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liposarcoma × Thoracic × Clear all
NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡